샘플 요청 목록

 카트 문의
시장보고서
상품코드
1536168

세계 포도상구균 감염 치료제 시장

Staphylococcal Infection Drugs
발행일: | 리서치사: 구분자 Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 183 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

포도상구균 감염 치료제 세계 시장은 2030년까지 68억 달러에 달할 전망

2023년에 60억 달러로 추정되는 포도상구균 감염 치료제 세계 시장은 분석 기간 2023-2030년에 CAGR 1.8%로 성장하고, 2030년에는 68억 달러에 이를 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 β-락탐 약물은 CAGR 2.6%로 성장을 지속하고, 분석 기간 종료 시 22억 달러에 달할 것으로 예측됩니다. 펩티드 의약 부문의 성장률은 분석 기간 동안 CAGR 1.8%로 추정됩니다.

미국 시장은 16억 달러로 추정, 중국은 CAGR 3.5%로 성장할 것으로 예측

미국 포도상구균 감염 치료제 시장은 2023년 16억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 13억 달러 규모에 이를 것으로 예측되며, 분석 기간 2023-2030년의 CAGR은 3.5%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 0.9%와 1.7%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 1.2%로 성장할 것으로 예측됩니다.

주요 동향과 촉진요인

다양한 포도상구균으로 인한 포도상구균 감염은 경미한 피부 염증에서 패혈증, 심내막염, 폐렴과 같은 생명을 위협하는 질병에 이르기까지 다양한 임상 증상으로 나타납니다. 이러한 감염의 치료는 과거에는 항생제에 의존하는 경우가 많았지만, MRSA(메티실린 내성 황색포도상구균)와 같은 항생제 내성 균주의 위협이 증가함에 따라 새로운 치료법의 필요성이 높아졌습니다. 현재 약물에 대한 내성이 증가함에 따라 연구자들은 파지 요법, 백신 개발, 숙주 면역계 조절 전략 등 신규 항생제 및 대체 치료법의 개발에 쫓기고 있습니다.

항생제 내성이라는 과제에 대응하기 위해 제약 업계는 알려진 내성 경로를 피할 수 있는 혁신적인 약제 메커니즘과 병용 요법에 점점 주력하고 있습니다. 또한 유전체 및 단백질체학 기술의 진보로 감염 유형을 보다 정확하게 파악할 수 있게 되어 표적 약물 개발 및 개인화 치료 접근법이 용이해지고 있습니다. 이 프리시전 메디신 접근법은 환자가 특정 감염 프로파일을 기반으로 가장 효과적인 약물을 확실하게 투여하도록 함으로써 치료 성적을 향상시킬 것으로 기대됩니다.

포도상구균 감염 치료제 시장 개척은 약물 내성 황색 포도상구균 감염의 발생률 증가, 원내 감염에 대한 인식과 감시 강화, 항균제 개발에 대한 규제 당국의 인센티브 강화 등 여러 요인에 의해 추진 되었습니다. 현재 진행 중인 연구와 투자는 새로운 박테리아 타겟의 확인과 기존 항생제의 약리학적 특성 강화에 중점을 둡니다. 한편, 세계 보건기관과 정부기관은 자금 지원 및 신약의 신속한 승인 과정을 통해 시장을 강화하고 효과적인 포도상구균 감염 치료에 대한 긴급한 요구에 대응하고 있습니다.

조사 대상 기업 예(주목의 86사)

  • AbVacc, Inc.
  • Acurx Pharmaceuticals
  • Aptorum Group
  • Armata Pharmaceuticals
  • Basilea Pharmaceutica Ltd.
  • BioVersys
  • Debiopharm Group
  • Destiny Pharma
  • Locus Biosciences, Inc.
  • Lytix Biopharma AS
  • Mabwell Biotech
  • TechnoPhage SA
  • Trellis Bioscience
  • Venus Remedies
  • Xellia Pharmaceuticals;

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

JHS 24.08.29

Global Staphylococcal Infection Drugs Market to Reach US$6.8 Billion by 2030

The global market for Staphylococcal Infection Drugs estimated at US$6.0 Billion in the year 2023, is expected to reach US$6.8 Billion by 2030, growing at a CAGR of 1.8% over the analysis period 2023-2030. Beta-Lactams Drugs, one of the segments analyzed in the report, is expected to record a 2.6% CAGR and reach US$2.2 Billion by the end of the analysis period. Growth in the Peptides Drugs segment is estimated at 1.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.6 Billion While China is Forecast to Grow at 3.5% CAGR

The Staphylococcal Infection Drugs market in the U.S. is estimated at US$1.6 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 3.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.9% and 1.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.2% CAGR.

Key Trends and Drivers

Staphylococcal infections, attributable to various Staphylococcus bacteria strains, manifest in a range of clinical conditions from minor skin irritations to life-threatening diseases like sepsis, endocarditis, and pneumonia. The treatment of these infections traditionally relies heavily on antibiotics, but the growing threat of antibiotic-resistant strains such as MRSA (Methicillin-resistant Staphylococcus aureus) has intensified the need for new therapeutic approaches. As resistance to current drugs escalates, researchers are driven to develop novel antibiotics and alternative treatments, including phage therapy, vaccine development, and host immune system modulation strategies.

In response to the challenge of antibiotic resistance, the pharmaceutical industry is increasingly focusing on innovative drug mechanisms and combination therapies that can circumvent known resistance pathways. Additionally, advancements in genomic and proteomic technologies are enabling more precise identification of infection types, which facilitates targeted drug development and personalized treatment approaches. This precision medicine approach is expected to improve treatment outcomes by ensuring that patients receive the most effective drugs based on their specific infection profile.

The growth in the market for staphylococcal infection drugs is driven by several factors, including the increasing incidence of drug-resistant staph infections, heightened awareness and surveillance of hospital-acquired infections, and stronger regulatory incentives for developing antibacterial agents. Ongoing research and investment are focused on identifying novel bacterial targets and enhancing the pharmacological properties of existing antibiotics. Meanwhile, global health organizations and governmental bodies are bolstering the market through funding and fast-track approval processes for new drugs, addressing the urgent need for effective staphylococcal infection treatments.

Select Competitors (Total 86 Featured) -

  • AbVacc, Inc.
  • Acurx Pharmaceuticals
  • Aptorum Group
  • Armata Pharmaceuticals
  • Basilea Pharmaceutica Ltd.
  • BioVersys
  • Debiopharm Group
  • Destiny Pharma
  • Locus Biosciences, Inc.
  • Lytix Biopharma AS
  • Mabwell Biotech
  • TechnoPhage SA
  • Trellis Bioscience
  • Venus Remedies
  • Xellia Pharmaceuticals;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Staphylococcal Infection Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rise of Antibiotic Resistance in Staphylococcal Infections
    • Development of Novel Antibacterial Agents
    • Advances in Rapid Bacterial Testing Technologies
    • Increased Incidence of Hospital-Acquired Infections
    • Growing Demand for Effective MRSA Infections Treatment
    • Impact of Global Health Initiatives on Antibiotic Development
    • Advances in Genomics and Pathogen Tracking
    • Public Awareness Campaigns and Education
    • Funding Increases for Antimicrobial Resistance Research
    • Adoption of Combination Therapy Strategies
    • Innovations in Vaccine Development for Staphylococcus Prevention
    • Economic Impact of Staph Infections on Healthcare Systems
    • Shift Towards Personalized Medicine and Tailored Therapies
    • Global Spread of Community-Acquired Staphylococcal Infections
    • Strategic Alliances Among Biopharma and Research Institutes
    • Patient-Centric Approaches in Drug Development
    • Challenges in Treating Multi-Drug Resistant Bacterial Strains
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Staphylococcal Infection Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Staphylococcal Infection Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Staphylococcal Infection Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Beta-Lactams Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Beta-Lactams Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Beta-Lactams Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Peptides Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Peptides Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Peptides Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Quinolones Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Quinolones Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Quinolones Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Macrolides Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Macrolides Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Macrolides Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • JAPAN
    • Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 26: Japan Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Japan Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Japan 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • CHINA
    • Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 29: China Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: China Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: China 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • EUROPE
    • Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Staphylococcal Infection Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Europe 16-Year Perspective for Staphylococcal Infection Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Europe 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • FRANCE
    • Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 38: France Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: France Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: France 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • GERMANY
    • Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 41: Germany Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Germany Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Germany 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Italy Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Italy 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 47: UK Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: UK Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: UK 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 50: Spain Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Spain Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Spain 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 53: Russia Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Russia Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Russia 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Rest of Europe Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Rest of Europe 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for Staphylococcal Infection Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Asia-Pacific 16-Year Perspective for Staphylococcal Infection Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Asia-Pacific 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 65: Australia Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Australia Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Australia 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • INDIA
    • Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 68: India Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: India Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: India 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 71: South Korea Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: South Korea Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: South Korea 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 74: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Rest of Asia-Pacific Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Rest of Asia-Pacific 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 77: Latin America Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 78: Latin America Historic Review for Staphylococcal Infection Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Latin America 16-Year Perspective for Staphylococcal Infection Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 80: Latin America Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Latin America Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Latin America 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 83: Argentina Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Argentina Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Argentina 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 86: Brazil Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Brazil Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Brazil 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 89: Mexico Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Mexico Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Mexico 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 92: Rest of Latin America Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Latin America Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Latin America 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 95: Middle East Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 96: Middle East Historic Review for Staphylococcal Infection Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Middle East 16-Year Perspective for Staphylococcal Infection Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 98: Middle East Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Middle East Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Middle East 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 101: Iran Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Iran Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Iran 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 104: Israel Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Israel Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Israel 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 107: Saudi Arabia Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Saudi Arabia Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Saudi Arabia 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 110: UAE Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UAE Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: UAE 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 113: Rest of Middle East Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Rest of Middle East Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Rest of Middle East 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • AFRICA
    • Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 116: Africa Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Africa Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Africa 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제